Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5094883 | 0.85 | SLC6A2 (0.46) | SLC6A2SLC6A4MRGPRX4AURKATPX2 | |
| SCHEMBL14930553 | 0.83 | CA1 (0.58) | MRGPRX4AURKATPX2FAAHEPHX2 | |
| SCHEMBL5101681 | 0.81 | NPSR1 (0.54) | SLC6A2SLC6A4MRGPRX4ERN1 | |
| SCHEMBL12225947 | 0.81 | ERN1 (0.56) | SLC6A2SLC6A4MRGPRX4AURKATPX2 | |
| SCHEMBL5095625 | 0.79 | AKR1C2 (0.48) | NOTUMMRGPRX4AURKATPX2EPHX2 | |
| SCHEMBL5089885 | 0.79 | ERN1 (0.45) | NOTUMMRGPRX4AURKATPX2LMNA | |
| SCHEMBL5089889 | 0.79 | ERN1 (0.45) | NOTUMMRGPRX4AURKATPX2LMNA | |
| SCHEMBL5089993 | 0.79 | CCR6 (0.53) | NOTUMMRGPRX4EPHX2CA1CA2 | |
| SCHEMBL2533347 | 0.79 | ERN1 (0.43) | SLC6A2SLC6A4MRGPRX4AURKATPX2 | |
| SCHEMBL514352 | 0.78 | CA1 (0.64) | MRGPRX4LMNAFAAHEPHX2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318760-B2 | Type 2 diabetes, atherosclerosis; compounds are N-(2-carboxyethyl)benzamides or N-tetrazolyl derivatives of benzamides; glucagon antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318760-B2 | Type 2 diabetes, atherosclerosis; compounds are N-(2-carboxyethyl)benzamides or N-tetrazolyl derivatives of benzamides; glucagon antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318760-B2 | Type 2 diabetes, atherosclerosis; compounds are N-(2-carboxyethyl)benzamides or N-tetrazolyl derivatives of benzamides; glucagon antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20080161347-A1 | Substituted Aryl and Heteroaryl Derivatives, Compositions Containing Such Compounds and Methods of Use | MERCK & CO., INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161347-A1 | Substituted Aryl and Heteroaryl Derivatives, Compositions Containing Such Compounds and Methods of Use | MERCK & CO., INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161347-A1 | Substituted Aryl and Heteroaryl Derivatives, Compositions Containing Such Compounds and Methods of Use | MERCK & CO., INC. (US) | 2008-07-03 | — | — | US | disclosed |
| EP-1933622-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | Renovis, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007109192-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2006102067-A1 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES | MERCK & CO., INC. (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161347-A1 | Substituted Aryl and Heteroaryl Derivatives, Compositions Containing Such Compounds and Methods of Use | GPR119, PNLIP, SLC5A2 | NOTUM 1300/4885SLC6A2 742/4885SLC6A4 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.